Who are the key players in North America U.S. In Vitro Diagnostics (IVD) Market industry?

The top 5 key players in the North America U.S. IVD Market are Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Becton Dickinson (BD), and Siemens Healthineers. These companies lead the market through innovative diagnostic solutions, extensive product portfolios, and strategic partnerships, driving advancements in diagnostic technologies.

Which segment accounted for the largest North America U.S. In Vitro Diagnostics (IVD) Market share?

The molecular diagnostics segment accounted for the largest market share in the U.S. IVD market. Its dominance is driven by rising demand for PCR and genetic testing for infectious diseases and oncology, supported by advancements from companies like Roche Diagnostics and Thermo Fisher Scientific.

What are the factors driving the North America U.S. In Vitro Diagnostics (IVD) Market?

Key drivers include increased prevalence of chronic and infectious diseases, technological advancements in diagnostics, and supportive government initiatives. For example, Becton Dickinson’s launch of high-throughput diagnostic systems has accelerated clinical workflow efficiency and enabled rapid results, fueling market expansion.

Which type accounted for the largest North America U.S. In Vitro Diagnostics (IVD) Market share?

Reagent and kits type held the largest share of the U.S. IVD market. This is attributed to their frequent and recurring use in laboratory and point-of-care testing, as well as continuous product launches, such as Siemens Healthineers’ new reagent kits for cardiac and infectious disease markers.

Home Healthcare

North America U.S. In Vitro Diagnostics (IVD) Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

Name: North America U.S. In Vitro Diagnostics (IVD) Market
Brand: Bussiness Insights

North America U.S. In Vitro Diagnostics (IVD) Market Market: by Type (Reagents & Kits, Instruments, Software & Services), Application (Infectious Diseases, Diabetes, Oncology, Cardiology, Nephrology, Autoimmune Diseases), Distribution Channels (Hospital Laboratories, Academic & Medical Schools, Point-of-Care Testing, Patient Self-Testing, Others), Technology (Immunoassay, Hematology, Clinical Chemistry, Molecular Diagnostics, Microbiology, Coagulation), Organization Size (Small, Medium, Large) and By North America Historical & Forecast Period (2020-2035) Comprehensive Study 2025

Last Updated: 31-07-2025 | Format: PDF | Report ID:20250 | Author: Lena

RD TOC Segmentation Research Methodology Request For Free Sample

North America U.S. In Vitro Diagnostics (IVD) Market Analysis, 2025-2035

The North America U.S. In Vitro Diagnostics (IVD) Market encompasses a range of diagnostic tests performed on biological samples to detect diseases, conditions, or infections. This market is pivotal in disease prevention, management, and treatment, offering real-time clinical insights that improve patient care outcomes. The sector includes reagents, kits, instruments, software, services, and is applied in areas such as infectious diseases, diabetes, and oncology, leveraging technologies like immunoassays, molecular diagnostics, and clinical chemistry. As healthcare evolves towards precision medicine, demand for IVD products continues to surge, with robust contributions from hospital labs, academic centers, and point-of-care solutions. Key players drive technological advancement, innovation, and expanded product portfolios to address emerging health burdens and diagnostic needs.

Latest Market Dynamics

Key Drivers

Rising prevalence of chronic and infectious diseases: Increasing cases of diabetes, cancer, and infectious diseases drive demand for advanced diagnostic tools. Companies like

Shift towards point-of-care (POC) testing: Rapid, easy-to-use IVD kits enable quicker clinical decisions in diverse healthcare settings. Siemens Healthineers is investing in POC diagnostics to allow decentralized testing for improved patient care.
Integration of artificial intelligence (AI): AI-powered IVD tools support automated analysis, predictive diagnostics, and personalized medicine approaches. Thermo Fisher Scientific incorporates AI in diagnostic solutions, optimizing result interpretation and workflow management.

Expansion into untapped markets and home-based/self-testing: Increasing consumer awareness and preference for home-based testing open new growth avenues. Hologic, Inc. has been expanding its self-testing portfolio for infectious disease diagnostics.
Development of multiplex diagnostic platforms: Simultaneous detection of multiple pathogens or biomarkers in a single run is a key area for growth. Bio-Rad Laboratories recently introduced multiplex molecular kits for respiratory and infectious diseases.

Stringent regulatory compliance and slow approval process: Ensuring product safety, efficacy, and regulatory alignment delays new product launches. Qiagen N.V. faces challenges accelerating regulatory approvals for novel assays in the U.S. market.
Data security and interoperability: Protecting sensitive patient data and ensuring seamless data integration across different IT platforms remains complex. Becton, Dickinson and Company (BD) is actively working to enhance data interoperability and cybersecurity in its IVD ecosystem.

High costs of advanced diagnostics: Capital investments required for cutting-edge diagnostic equipment limit adoption in resource-constrained settings. Smaller labs may find Sysmex Corporation’s hematology analyzers financially inaccessible.
Scarcity of skilled laboratory professionals: Limited pool of trained technicians and diagnosticians hampers expansion and efficient use of sophisticated IVD tests. Ortho Clinical Diagnostics is offering remote-training solutions to address workforce shortages in lab diagnostics.

In 2025, reagents & kits take the largest share of the North America U.S. IVD market, owing to their recurring use in high-volume operations and their essential role in diagnostic workflows. Instruments account for a significant share as advanced analyzers are vital for complex tests, while software & services gain momentum through digital transformation and cloud integration initiatives. The focus on laboratory automation, alongside demand for reliable consumables and calibrators, is shaping procurement decisions across hospitals and labs.

By application, infectious diseases represent the largest share of the North America U.S. IVD market in 2025 due to a persistent need for fast, accurate diagnostics in light of global health threats like COVID-19 and emerging pathogens. Diabetes and oncology applications are also significant contributors, reflecting rising prevalence and prioritization of early detection in clinical protocols. Enhanced focus on population health management and personalized medicine further propels demand for robust diagnostic assays.

Market revenue for the North America U.S. IVD sector shows robust growth between 2020 and 2035. Starting around USD 16,700 Million in 2020, revenues are projected to increase steadily with a CAGR of around 6.2%, reaching approximately USD 47,800 Million by 2035. Expansion is fueled by the growing burden of chronic diseases, technological evolution in diagnostics, and proactive healthcare infrastructure investments across the region. The U.S. maintains leadership, with Canada and Mexico exhibiting promising growth trends.

Year-on-Year (YOY) growth for the IVD market in North America shows moderate to strong upward movement. The market witnessed a YOY spike in 2020-2021 owing to pandemic-driven demand, stabilizing to healthy single-digit rates through 2025. Ongoing trends in laboratory automation, chronic disease management, and POC diagnostic adoption are expected to sustain a 5-7% annual growth rate over the period, with new technology cycles further stimulating the market post-2030.

The United States dominates the North America U.S. IVD market in 2025 with a commanding 83% share, attributed to advanced infrastructure, high healthcare expenditure, and leading company headquarters. Canada follows with a 10% market share, benefitting from increasing R&D activities and government initiatives. Mexico, with a 7% share, shows steady uptake of IVD solutions as public health investments rise and private labs expand diagnostic capacities.

In 2025, Abbott Laboratories holds the largest player share at 23%, leveraging its broad diagnostics portfolio and robust distribution network. Roche Diagnostics claims 19% driven by dedicated molecular platforms and infectious disease assays, while Siemens Healthineers secures 15% owing to their extensive solutions in clinical chemistry and POC. Other notable contributors include Danaher Corporation and Thermo Fisher Scientific, each innovating to gain incremental market share through strategic partnerships and acquisitions.

Hospital laboratories constitute the primary buyers in the 2025 IVD market, representing 41% of total procurement. Point-of-care (POC) testing accounts for 28%, reflecting the paradigm shift towards rapid and decentralized testing. Academic & medical schools make up 15%, underlining their critical role in clinical research and training. Patient self-testing is also gaining momentum, as individuals seek greater involvement in personal health management.

Metrics	Details
Years	2020-2035
Base Year	2025
Market Size	23000
Regions	US, Canada, Mexico
Segments	By Type: Reagents & Kits, Instruments, Software & Services, Consumables, Calibrators & Controls, Accessories; By Application: Infectious Diseases, Diabetes, Oncology, Cardiology, Nephrology, Autoimmune Diseases
Players	Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Danaher Corporation, Bio-Rad Laboratories, Thermo Fisher Scientific, Becton Dickinson and Company (BD), Sysmex Corporation, bioMérieux SA, Ortho Clinical Diagnostics, Hologic Inc., Agilent Technologies, Qiagen N.V., Illumina Inc., PerkinElmer Inc.

June 2024: Abbott Laboratories introduces an upgraded Alinity™ m molecular platform for multi-pathogen detection, accelerating infectious disease diagnostics across North America.
July 2024: Roche Diagnostics receives emergency use authorization from the FDA for a new multiplex PCR assay targeting respiratory viruses.
August 2024: Siemens Healthineers partners with Mayo Clinic to co-develop AI-powered IVD tools for precision oncology diagnostics.
September 2024: Thermo Fisher Scientific acquires a digital health company to strengthen its cloud-based diagnostic services portfolio.
October 2024: Becton, Dickinson and Company (BD) launches a nationwide digital training initiative to address laboratory workforce shortages and enhance operational efficiency.

About the Author

Lena

Senior Research Consultant

Lena is a Senior Research Consultant specializing in market research, industry analysis, and business consulting across Healthcare. Lena brings a commercially grounded perspective to sectors shaped by changing demand, innovation, and competitive dynamics, helping turn complex market trends into clear strategic insights for business decision-makers. With 10+ years of experience across research, analytics, and strategic advisory roles, Lena has helped organizations translate data into actionable growth strategies.

HealthcareMarket ResearchIndustry AnalysisStrategic Consulting

Key Questions Answered

»What is the market size and growth rate of the global and regional market by various segments?
»What is the market size and growth rate of the market for selective countries?
»Which region or sub-segment is expected to drive the market in the forecast period?
»What factors are estimated to drive and restrain the market growth?
»What are the key technological and market trends shaping the market?
»What are the key opportunities in the market?
»What are the key companies operating in the market?
»Which company accounted for the highest market share?

Download Sample

Why Choose Bussiness Insights?

»Strong Industry Focus
»Extensive Product Offerings
»Customer Research Services
»Robust Research Methodology
»Comprehensive Reports
»Latest Technological Developments
»Value Chain Analysis
»Potential Market Opportunities
»Growth Dynamics
»Quality Assurance
»Post-sales Support
»Regular Report Updates

Speak to Analyst

North America U.S. In Vitro Diagnostics (IVD) Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

North America U.S. In Vitro Diagnostics (IVD) Market Analysis, 2025-2035

Latest Market Dynamics

Key Drivers

Key Trends

Key Opportunities

Key Challenges

Key Restraints

IVD Market Share by Type, 2025

IVD Market Share by Application, 2025

North America U.S. IVD Market Revenue (USD Million), 2020-2035

IVD Market Year-on-Year Growth Rate (%), 2020-2035

Market Share by Region, 2025

Market Share by Key Players, 2025

Market Share by Buyer Type, 2025

Study Coverage

Key Recent Developments

Frequently Asked Questions

About the Author

Related Reports